Climb Bio (CLYM) Equity Ratio (2020 - 2026)

Climb Bio has reported Equity Ratio for 7 years, with the latest figure at 0.97 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 0.88% year-over-year to 0.97; the trailing twelve-month figure through Mar 2026 stood at 0.97 (up 0.88% YoY), and the FY2025 full-year result was 0.96, down 1.94% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.97, up from 0.96 in the prior quarter.
• The five-year high for Equity Ratio was 0.98 in Q3 2024, with the low at 0.95 in Q2 2022.
• Historically, Equity Ratio has averaged 0.97 across 5 years, with a median of 0.97 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio jumped 300.58% — and 2025, when it fell 1.94%.
• Climb Bio's Equity Ratio stood at 0.95 in 2022, then climbed by 2.15% to 0.97 in 2023, then climbed by 0.16% to 0.98 in 2024, then fell by 1.94% to 0.96 in 2025, then grew by 1.59% to 0.97 in 2026.
• The last three Equity Ratio figures came in at 0.97 (Q1 2026), 0.96 (Q4 2025), and 0.97 (Q3 2025), per Business Quant data.